EUTM file information

017192758

CARMA

September 10, 2017

Trademark Summary

The trademark CARMA was filed by MaxCyte, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on September 26, 2017, and received one opposition filed on December 26, 2017 by CARMAT on Likelihood of confusion. the opponent was represented by GEVERS & ORES and proceedings were handled in English, and the oppositon was dismissed by the Euorpean Union Intellectual Property Office with decision issued December 26, 2017

The application was filed in English, and English was also language of all opposition proceedings (German was selected as the second language).

Appointment and Replacement of representative of the trademark registration was recorded on December 17, 2020. Change of name and address of the trademark registration was recorded on March 23, 2023.

Goods And Services

  • The mark was filed in class 5 with Cells for medical or clinical use and Gene therapy products, namely, genetically engineered tissues for transplant purposes..
  • The mark was filed in class 9 with Scientific apparatus for cell modification and scientific apparatus and instruments for scientific research and development, namely, electroporation apparatus, in International Class 09..
  • The mark was filed in class 10 with Medical devices used in connection with cell therapy for treatment of diseases with the exception of spinal prosthetics, spinal fusion implants, instruments for spinal surgery, bone fixation devices and sternal fixation devices and all the aforementioned goods being exclusively aimed for disease treatment via cell therapy..
  • The mark was filed in class 42 with following description of goods:
    1. Scientific research services in the field of cell modification and biological, scientific, and medical research and consultation services related thereto
    2. Product research and development in the fields of biology and medical sciences
    3. Providing laboratory research services in the field of gene expression, namely, cancer biology
    4. All the aforementioned services being exclusively aimed for disease treatment via cell therapy.